Categories: Wire Stories

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

– Company to Host Conference Call and Webcast on May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT)


SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Wednesday, May 8, 2024. The Company will host a live conference call and webcast on Thursday, May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT).

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company’s website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.

Details are as follows:

Registration Link: https://register.vevent.com/register/BIb8622a7cf98e46cd9bc9198a5f105c36

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

A replay will be available shortly after the call and can be accessed by visiting the Company’s website.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

Contacts

Investor Relations:
Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:
Shaun Maccoun / Xiaoyu Chen

+1 (415) 317-7255 / +86 185 0015 5011

shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Alex

Recent Posts

Hong Kong Design Centre Welcomes ‘Blueprint for Arts and Culture and Creative Industries Development’

HONG KONG SAR - Media OutReach Newswire - 27 November 2024 - Hong Kong Design…

30 minutes ago

Preserving the beauty of nature – a bond that links Lancang-Mekong countries

CHENGDU CITY, CHINA - Media OutReach Newswire - 27 November 2024 - Taking its source…

30 minutes ago

Arirang TV presents Korea’s one-day trip entertainment show “¡Hola, Corea!” for South American viewers

- Arirang TV's one-day trip entertainment “¡Hola, Corea!”, specially produced for South American viewers, will…

2 hours ago

Gartner Announces the Gartner CFO & Finance Executive Conference 2025 in Sydney

--(BUSINESS WIRE)--Gartner, Inc. (NYSE: IT): What:   Gartner CFO and Finance Executive Conference 2025  …

2 hours ago

Northern Trust Asset Management 2025 Global Investment Outlook: Expect U.S. Stocks to Outperform; High Yield Bond Market Is Attractive

Earnings Growth Backs U.S. Equities; Strong Credit Quality Supports High Yield Market; U.S. Money Market…

2 hours ago

S.BIOMEDICS Investigational Cell Therapy for Parkinson’s Disease With TED-A9 Shows Positive Data at 12-months in Phase 1/2a Clinical Trial

TED-A9 is high-purity ventral midbrain dopaminergic progenitor cells derived from human embryonic stem cells (hESCs)…

2 hours ago